Spotlight: Off-the-shelf is working: Now what has to change to scale it responsibly?

Remission without bespoke manufacturing: What recent European clinical results in aggressive leukaemias show about the true potential of off-the-shelf CAR-T and NK therapies and how this changes assumptions around speed, access, and scalability.

Safety profiles under scrutiny: How manageable safety signals are being achieved in specific patient groups and what design choices matter most in maintaining that balance as programmes expand.

From signal to system readiness: What these early successes imply for manufacturing scale, clinical site readiness, and regulatory confidence in Europe.